SINTX Technologies posts Q2 loss, revenue beats forecasts

SINTX Technologies Inc. reported a second-quarter loss of 8 cents per share, missing market expectations by 8 cents, while revenue of $1.2 million topped the $1.1 million forecast.

The biotechnology company attributed the earnings shortfall to higher research and development costs and lower-than-anticipated product sales. Revenue growth was driven by a 15% increase in government contract funding, partially offset by a decline in commercial product revenue.

Shares of SINTX fell 5% in extended trading following the release, extending a 12% decline over the past month. Analysts had expected a loss of 0 cents per share on revenue of $1.1 million, according to a Refinitiv consensus.

The company, which develops silicon nitride-based medical and dental implants, has faced margin pressure amid rising material and labor expenses. Management reaffirmed its full-year revenue guidance of $4.5 million to $5.0 million but did not provide an updated earnings outlook.

SINTX has been expanding its pipeline of orthopedic and spinal products, though commercialization timelines remain subject to regulatory approvals. The firm’s cash position stood at $2.3 million as of June 30, providing a buffer for near-term operations.

Investors will monitor upcoming clinical trial updates and potential partnerships as key catalysts for the stock in the coming quarters.